Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (131 reviews)

For research use only.

Catalog No.S1091

131 publications

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 131 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01028-8

PubMed: 33403501 ( click the link to review the publication )

Cell Signal, 2021, 80:109911

PubMed: 33422645 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Theranostics, 2020, 10(26):12204-12222

PubMed: 33204338 ( click the link to review the publication )

Cell Rep, 2020, 33(3):108293

PubMed: 33086062 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3717

PubMed: 33322337 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Mol Neurobiol, 2020, 57(3):1570-1593

PubMed: 31797328 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )
Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 44(4):1649-1661

PubMed: 32945502 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biol Pharm Bull, 2020, 10.1248/bpb.b20-00362

PubMed: 32863294 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Aging Cell, 2019, 18(3):e12932

PubMed: 30884121 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

J Agric Food Chem, 2019, 67(34):9510-9521

PubMed: 31382738 ( click the link to review the publication )
Biochimie, 2019, 163:108-116

PubMed: 31185266 ( click the link to review the publication )

Mol Med Rep, 2019, 19(4):2825-2830

PubMed: 30720075 ( click the link to review the publication )

Exp Ther Med, 2019, 17(3):1663-1669

PubMed: 30867686 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Genes Dev, 2018, 32(13-14):915-928

PubMed: 29945888 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Mol Cancer, 2018,

PubMed: 29455661 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )
Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4014-4025

PubMed: 28619711 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28534511 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Mol Cancer Res, 2017,

PubMed: 28289161 ( click the link to review the publication )

Endocrinology, 2017,

PubMed: 29028997 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28002807 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )
Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

Mol Cancer, 2015,

PubMed: 26041671 ( click the link to review the publication )

J Bone Miner Res, 2015, 30(11):1959-68

PubMed: 25990470 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cancer Res, 2015,

PubMed: 26263910 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116895

PubMed: 25603314 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26515601 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Neoplasia, 2014, 16(10):824-34

PubMed: 25379019 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )
Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
A4-Fuk	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFPRcY5KSzVyPUCuNFI5ODZizszN	M2HIPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
KS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUjJR\|UxRTBwMEO4N\|Uh\|ryP	NWfWXpNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
TE-11	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUXJR\|UxRTBwMEe4NlIh\|ryP	MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-1	NIrYVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPKTWM2OD1yLkC4OVg2KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HMV-II	NIfQcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEj2PZhKSzVyPUCuNFg5PDZizszN	NXHq[2dGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
COLO-205	NGnoT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXjUN\|ZWUUN3ME2wMlExPDV2IN88US=>	M{PMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ES1	M3HKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXrrdoRmUUN3ME2wMlExPjl4IN88US=>	M1H4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GDM-1	NUTreWNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkPUTWM2OD1yLkGzOlczKM7:TR?=	NY\pRmE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ML-2	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVPtZXJqUUN3ME2wMlE2QDl4IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Saos-2	NH24TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILwPJNKSzVyPUCuNVY2OjZizszN	M2Dpc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1355	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVK4Xo1rUUN3ME2wMlE5OTN3IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
G-401	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY\JR\|UxRTBwMUiyN{DPxE1?	MljyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-16	MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlLOTWM2OD1yLkG4O\|c4KM7:TR?=	Mkj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-7	NGC5T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlrITWM2OD1yLkG4PFgyKM7:TR?=	M2DR[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H727	NUH4Z\|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGnnN5dKSzVyPUCuNVk4QTRizszN	M{jjWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LCLC-97TM1	M4DHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjUbo83UUN3ME2wMlIxQTV3IN88US=>	MlzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H650	NIfufXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmeyTWM2OD1yLkKxN\|g1KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2122	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M13FO2lEPTB;MD6yN\|I6QSEQvF2=	M13adVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-N-DZ	M2\m[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV3JR\|UxRTBwMkO2PVgh\|ryP	NIjmeVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HT-29	NVPVRohDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXPJR\|UxRTBwMkSyOFgh\|ryP	Mkf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB771-HNC	NE\ZN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1\UUmlEPTB;MD6yOVkyPSEQvF2=	NIqyNWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HT-144	NVTa[ZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3LmVWlEPTB;MD6yOlE6OSEQvF2=	NFrscFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LAN-6	Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1jHVWlEPTB;MD6yOlM1QCEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EW-18	M3L4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoT4TWM2OD1yLkK3NFAyKM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LS-1034	M{e2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUnJR\|UxRTBwMkexN\|Ih\|ryP	MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-11	M2jwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYDJR\|UxRTBwMki0N\|Ih\|ryP	NFjXcIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SNU-C1	NFzSUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF7lO2xKSzVyPUCuNlk{OTNizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
RS4-11	M3vLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NILIZYxKSzVyPUCuN\|M4PThizszN	NGTET5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ES4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXLMNlR6UUN3ME2wMlQyODN6IN88US=>	MlrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-320-HSR	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYnJR\|UxRTBwNEGzOlgh\|ryP	NWHrTFhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NB10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXvyOG4yUUN3ME2wMlQ2PDN5IN88US=>	NFqwT2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BFTC-905	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH7DfI5KSzVyPUCuOFY4PThizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
A375	M1nyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV7QXYt2UUN3ME2wMlQ4PjF5IN88US=>	NFPFR4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SJRH30	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXzYZ45MUUN3ME2wMlUxQDJ{IN88US=>	NHXIVoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NOS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUWzV4dzUUN3ME2wMlUzOjZ5IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SIG-M5	NY\weVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3joTGlEPTB;MD61N\|U2PyEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DOK	NGTzZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1Swb2lEPTB;MD61OVYh\|ryP	NYjnVlh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NB69	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHm0dHdKSzVyPUCuOVgzPTdizszN	MkLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-NEP-1	M3fkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;TN4hKSzVyPUCuOlAzOzZizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MM-2	NHr6XVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2XLT2lEPTB;MD62OVQ6OSEQvF2=	M2PaWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H358	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{[0Z2lEPTB;MD62O\|A5OiEQvF2=	MnX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
RH-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHzFd\|NKSzVyPUCuO\|Q5PTlizszN	MlK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NH-12	NGTXNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUf6c4N[UUN3ME2wMlc3ODR4IN88US=>	NXTkZpRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
TE-12	NGnMPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIjqNXlKSzVyPUCuO\|Y1QDZizszN	NFXBNlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-668	NXXnTYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrw[4pKSzVyPUCuPFQ3PjZizszN	MmrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
PANC-08-13	M37YRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoPXTWM2OD1yLki2N\|c4KM7:TR?=	NVj5fYllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HCC2998	M4nyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYTJR\|UxRTBwOEiyOlMh\|ryP	Ml7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ABC-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn;jTWM2OD1yLkmwN\|UzKM7:TR?=	NXLMeZcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ES6	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVvuXnZbUUN3ME2wMlkyODZ4IN88US=>	Mmn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNU-387	NXHvdZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFe3T\|JKSzVyPUCuPVk{QTNizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CMK	NG\0dZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYXJR\|UxRTBwOUm5Nlkh\|ryP	NXW1fm5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SJSA-1	M2PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MonXTWM2OD1zLkCzOlU{KM7:TR?=	NVi0OII2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SIMA	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGrNNGZKSzVyPUGuNFY5OjVizszN	NX3aTJBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ES3	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHi3Tm9KSzVyPUGuNVIzQTdizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
IGROV-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVTJR\|UxRTFwMUW0OFQh\|ryP	M{H6UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MEL-JUSO	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEH1e2dKSzVyPUGuNVU4PTlizszN	NWXmOmVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
T84	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4W2[mlEPTB;MT6yNFkyPCEQvF2=	M3fhXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CAL-85-1	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml;2TWM2OD1zLkKzNVM5KM7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
RD	M3XUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1zuSmlEPTB;MT6yOlQ2PSEQvF2=	M1XSbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-8	M1nQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVnJR\|UxRTFwM{G0OlIh\|ryP	MmHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
L-363	M{W3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYC4OHk5UUN3ME2xMlM1OjB6IN88US=>	Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EKVX	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlfHTWM2OD1zLkO0OVY5KM7:TR?=	M2m1e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SK-MEL-3	M4nnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\4ZWlEPTB;MT60PFU2PiEQvF2=	NVPoZZEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
TGBC24TKB	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\lO5VKSzVyPUGuOVAyQTNizszN	M4\zPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1770	M3uz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV:1eWo{UUN3ME2xMlUyOTF\|IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HuH-7	NIK0NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mli0TWM2OD1zLk[wNFk5KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HL-60	M2Lv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVvJR\|UxRTFwNk[5Nlgh\|ryP	M4HKdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXTJR\|UxRTFwN{C5OFUh\|ryP	NFW5dlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LC-2-ad	NHH3NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVPJR\|UxRTFwN{O4PFch\|ryP	M4jJcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LB647-SCLC	NG\0eGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2PWd2lEPTB;MT63OlU5OyEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2171	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWS1V2NxUUN3ME2xMlc4PzF4IN88US=>	NV:xRWh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-PN-DW	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWnu[lFoUUN3ME2xMlkyOjl6IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MC-IXC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGf1b5lKSzVyPUGuPVg6QCEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LS-513	NYHGNXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2j4fWlEPTB;Mj6wOVMxPSEQvF2=	MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-3	NHvaVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVS4XmpkUUN3ME2yMlA6QDR2IN88US=>	NH7MSIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OPM-2	NHPvW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUjFV3dFUUN3ME2yMlExOiEQvF2=	NHzZRlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LP-1	M3HMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkXHTWM2OD1{LkK1PFA4KM7:TR?=	NV32T21LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LU-134-A	NYC3ZVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUXWfmNoUUN3ME2yMlI4PyEQvF2=	NV3XdohHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CP66-MEL	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFXM[HhKSzVyPUKuNlkxOTRizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HCC1143	M1zpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVXPUpZ[UUN3ME2yMlQ2OzZ6IN88US=>	M2D6bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LOXIMVI	M{Cxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\PVGlEPTB;Mj62NFIyKM7:TR?=	MkHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TE-10	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV3BTXU4UUN3ME2yMlcxQDN6IN88US=>	NWT1T3hzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1882	NUjySZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M13Z[GlEPTB;Mj63OVIzPyEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CHP-126	NXLsdFFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYLJR\|UxRTJwN{[zNVch\|ryP	MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1623	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3zMO2lEPTB;Mj65NlAzPCEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GB-1	NVy1W\|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYTJR\|UxRTJwOUO0NFQh\|ryP	M1TNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
RCC10RGB	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXLJR\|UxRTJwOUWyPFEh\|ryP	NIHZOoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2141	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkfCTWM2OD1{Lkm2PFk3KM7:TR?=	NEnufVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
GI-ME-N	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVWwSVBjUUN3ME2zMlAxPTZ3IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H526	NFjB[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUPJR\|UxRTNwMESwPFUh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H747	M1Xyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIP3T3pKSzVyPUOuNFQ6QTJizszN	MkLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNU-423	NVjQSlFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3nlO2lEPTB;Mz6yNFMyOyEQvF2=	M2\vRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A427	NGDvZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3;XRmlEPTB;Mz6yOVY6QSEQvF2=	NHjqb\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAL-12T	NILhbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlrqTWM2OD1\|LkSwO\|E{KM7:TR?=	M{HXRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LU-99A	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFvKc5NKSzVyPUOuOFcyODVizszN	NVH3dotuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MS-1	NFnrZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUTJR\|UxRTNwNUO0Nlkh\|ryP	MlOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-LU-1	NX7BdJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDvTWM2OD1\|Lke2Nlk2KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SW837	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4\acGlEPTB;Mz63OlM{OyEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES8	NV3KcXozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\IcGlEPTB;Mz64N\|g4PyEQvF2=	M1jGXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MZ2-MEL	M4rITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjrb2FFUUN3ME2zMlkzODh4IN88US=>	M2HPcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TGW	M{LvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlnKTWM2OD12LkCxN\|EyKM7:TR?=	M1nMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GP5d	NHjLcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NU\Vc5dCUUN3ME20MlA2OzZ{IN88US=>	NI\WdJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BB49-HNC	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmjxTWM2OD12LkG1NlE{KM7:TR?=	NHX3cZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB13	NF3wXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHS2bppKSzVyPUSuNlY5QDdizszN	NXPPWXRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NTERA-S-cl-D1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWfJR\|UxRTRwMki2NVUh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1648	NGWwTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVHuOYZ5UUN3ME20MlI6QDF7IN88US=>	M3u5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LCLC-103H	M4fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkD1TWM2OD12LkOyNVk2KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LS-411N	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mo[wTWM2OD12LkS0PFg2KM7:TR?=	M2LvelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1092	M1XLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLBTmpEUUN3ME20MlQ2Pjh5IN88US=>	NVnDXHdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PANC-10-05	M3;V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1fMeGlEPTB;ND62PVg1KM7:TR?=	NHfofZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DK-MG	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWXJR\|UxRTRwOEC5N\|Mh\|ryP	MnvlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
OVCAR-5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{jzSGlEPTB;ND64NVIzPiEQvF2=	NYnQWG5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CAL-39	NY[2VmFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MULJR\|UxRTRwOEe2O{DPxE1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TE-441-T	NVTEbXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYi3T\|EzUUN3ME20MlkxPTN5IN88US=>	NXWwW5lqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MOLT-16	NYTFbmg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXvpVWhlUUN3ME20Mlk2OjV\|IN88US=>	Mlz2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MCF7	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoDZTWM2OD13LkG0OVE4KM7:TR?=	NYfXUXFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CAPAN-1	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYK4dmFGUUN3ME21MlI2PzB5IN88US=>	M3PKPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PSN1	NWjqOmI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M170fWlEPTB;NT6yO\|I{PSEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H292	NH2xSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUXJR\|UxRTVwM{CwOFQh\|ryP	NXy1TZJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CPC-N	NIDkXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHjJem1KSzVyPUWuN\|k1OTlizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DoTc2-4510	MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVu2WG02UUN3ME21MlQ2OzdzIN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	NUjncpliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTVwNUW5N\|Mh\|ryP	MlfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MHH-ES-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mmr4TWM2OD13LkW5PVA4KM7:TR?=	MnLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NMC-G1	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU\JR\|UxRTVwN{CyNlch\|ryP	NH7tVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1710	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVvJR\|UxRTVwN{S3OVEh\|ryP	NWfGfIwzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
YAPC	NFHrOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYfJR\|UxRTVwN{[yNFEh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
22RV1	NHr3e5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1vxW2lEPTB;NT64NFAyQSEQvF2=	NHq5dI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-679	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmjtTWM2OD13Lki4PVQ5KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TCCSUP	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn3FTWM2OD13LkmzNlU6KM7:TR?=	MkDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
C2BBe1	NGjS[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmnKTWM2OD13LkmzPVch\|ryP	MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TE-15	NH7HfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUHWeXRWUUN3ME22MlA3PjB3IN88US=>	NHXt[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SCLC-21H	M2CyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2PCdWlEPTB;Nj6xNFg1OyEQvF2=	NIPhO\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
EoL-1-cell	NWnVeWpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVLJR\|UxRTZwMU[1OlMh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NKM-1	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3:2NmlEPTB;Nj6xOlcyKM7:TR?=	MnfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1304	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTwb\|d3UUN3ME22MlI4PDJ6IN88US=>	MorCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NB6	NHTPXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLjWolKSzVyPU[uNlk3OjJizszN	NYK3SJo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NALM-6	M3\mfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVjJR\|UxRTZwM{OyN{DPxE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H522	NFHGSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFfPTpJKSzVyPU[uN\|M{ODZizszN	NXHDbnIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MV-4-11	M{DnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX\JR\|UxRTZwM{ewO\|kh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	NV3RSoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXwZlBZUUN3ME22MlM5PjZ5IN88US=>	MoDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1417	NUfzOnM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUfJR\|UxRTZwNEC4OFch\|ryP	NH:z[GY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HT-1197	M2CxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4nsZmlEPTB;Nj61O\|EzOiEQvF2=	M4DzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
P30-OHK	NHqxW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDRTWM2OD14Lk[yO\|ch\|ryP	M4jnOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ALL-PO	NYK5SGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVXJR\|UxRTZwN{G5NVYh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
OVCAR-4	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY\JR\|UxRTZwN{W0NFUh\|ryP	NHzxZYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HCC2157	NH7rXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MULJR\|UxRTZwN{e0O\|Uh\|ryP	NIrtd2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H838	M2L1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVfJR\|UxRTZwOU[0PUDPxE1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1299	NXTpbIVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mlm4TWM2OD14Lkm3NFkh\|ryP	M{WzfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SW954	NF\GVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEP5[VFKSzVyPUeuNlAxPjhizszN	M3rrWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H441	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXexOGxoUUN3ME23MlM1ODZ3IN88US=>	NHnFVXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-MEL-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFPa[pJKSzVyPUeuOFg{PzNizszN	NWfGTIJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KARPAS-45	M2nYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEPVN3dKSzVyPUeuOlU6OjlizszN	NWS5RlhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CAL-54	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXPvXIxmUUN3ME23MlgzQTd5IN88US=>	NGS2Z2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-180	NYL2VphuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHHqXmdKSzVyPUeuPFg6PDFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H187	NUK5bJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnfLTWM2OD15Lkm1PVQ4KM7:TR?=	NVrEUnA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RT-112	NF\mXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MU\JR\|UxRThwMEm2O\|ch\|ryP	NI\V[mk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1437	NFHyWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2LxOmlEPTB;OD6wPVc6PSEQvF2=	NVvvcYtnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNU-449	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFfMeoJKSzVyPUiuNlgzPzJizszN	MlzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HCC1187	M4n0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlrTTWM2OD16LkK5N\|kyKM7:TR?=	MnvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2030	M3HoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXHyd\|JVUUN3ME24MlM4PzF2IN88US=>	MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HuO-3N1	M3PHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4jITGlEPTB;OD6zO\|g1PCEQvF2=	MkfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-792	MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWnHWnNYUUN3ME24MlQyPTJ5IN88US=>	NHjWWpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHv5R2xKSzVyPUiuPFU2ODhizszN	NULxT\|llRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-N-FI	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfDRlQ4UUN3ME25MlA1OjVizszN	NV\ifnIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MMAC-SF	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3PIR2lEPTB;OT6wPVc2OSEQvF2=	M17tN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H28	NFLJXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWjMVlFrUUN3ME25MlExPDZ7IN88US=>	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ETK-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIn0SWtKSzVyPUmuNlk6PzRizszN	Mk\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1993	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVjJR\|UxRTlwNESyOlEh\|ryP	NIf1bW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
no-11	NVnlXlJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXvxRYhXUUN3ME25MlQ4OTJizszN	NIHBU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ChaGo-K-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUnJR\|UxRTlwNUG1PFMh\|ryP	NEO5c2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCCIT	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1L0b2lEPTB;OT61N\|E3QSEQvF2=	NGDBNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SAS	NVrFTmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml7UTWM2OD1zMD6yOFgh\|ryP	NGP3Oo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A673	NWq3TGlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MljFTWM2OD1zMD6zO\|A1KM7:TR?=	M1j3TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1522	NGjaXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIDL[oVKSzVyPUGwMlM4ODdizszN	MonTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H810	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY\JR\|UxRTFyLkO5NFch\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
IST-MES1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYTJR\|UxRTFyLkS1OlQh\|ryP	M4LySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GR-ST	NVjWNIFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGP1ZnJKSzVyPUGwMlUxOjRizszN	M4D4[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SUP-T1	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITFPZpKSzVyPUGwMlc{OTdizszN	NXzYeGxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NB5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXi1OmVTUUN3ME2xNE46ODJ{IN88US=>	NGjZc2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MZ1-PC	NIXmVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYHjc\|dGUUN3ME2xNE46PTdzIN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-CO-1	M3jkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWDLVGtyUUN3ME2xNE46QTNzIN88US=>	M1TJe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
Capan-2	NV;r[WxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3OxZWlEPTB;MUGuN\|E6QCEQvF2=	NULMVmdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
697	NX3BWm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWnh[VhGUUN3ME2xNU43PzV5IN88US=>	NXTRZXJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
REH	NXvIdIZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVXJR\|UxRTFzLke0OVEh\|ryP	M4fld\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GI-1	NFLHOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWDJR\|UxRTFzLki2NVUh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BB65-RCC	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn3pTWM2OD1zMj6wPVE3KM7:TR?=	MlPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1651	NG\ZUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDpTWM2OD1zMj6yOFc5KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1618	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33sT2lEPTB;MUKuN\|k4PiEQvF2=	NIWxN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2081	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVfJR\|UxRTF{Lk[xOFEh\|ryP	M2H6OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GCIY	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUj0[XB1UUN3ME2xNk44OjF\|IN88US=>	M2jBSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NY	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYnJR\|UxRTF\|LkC2OFMh\|ryP	M2rMVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PANC-03-27	NHfNW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWSzV\|BKUUN3ME2xN{4xQDB5IN88US=>	NWmzUVl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BHY	M3fJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYPjSItIUUN3ME2xN{4zOTJzIN88US=>	MlriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-OV-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1G3dWlEPTB;MUOuN\|c3OyEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
5637	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1vaRWlEPTB;MUOuO\|c2QSEQvF2=	M3f5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LC-1F	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NW[5V4FuUUN3ME2xOE4xOzV4IN88US=>	NVPhbIZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SNB75	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYDoZ5NIUUN3ME2xOE4xOzh\|IN88US=>	M{Duc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CHP-212	NIPRd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXvJR\|UxRTF2LkC0OlQh\|ryP	NYHyOGVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HT-1376	MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUnJR\|UxRTF2LkGxNlYh\|ryP	NIXUNYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MONO-MAC-6	M2LMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M33JfGlEPTB;MUSuNVUxOiEQvF2=	NET0WWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CA46	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2LobmlEPTB;MUSuNVgzPyEQvF2=	M2HQZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SCC-15	NHjyZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVfJR\|UxRTF2LkW1PFMh\|ryP	MmqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ATN-1	MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYLJR\|UxRTF2Lk[2Nlch\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2405	NEn3R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEficXRKSzVyPUG0MlgyPTdizszN	NVfzRYNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H716	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XBR2lEPTB;MUSuPFQ6OyEQvF2=	NFTTTnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW620	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnS5TWM2OD1zND65NFE1KM7:TR?=	NWPrVWFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H226	M{LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{[wfGlEPTB;MUSuPVA5PSEQvF2=	M4HSVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SW962	M4HQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2nMPWlEPTB;MUSuPVQ{OiEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KYSE-150	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmjXTWM2OD1zND65OVUh\|ryP	M3T6c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
OCUB-M	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXrqemY5UUN3ME2xOE46QDh\|IN88US=>	NEKzVoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ES7	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFj0SIhKSzVyPUG1MlA6QDRizszN	M1vpXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SW1463	NIf4ZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLm[YZKSzVyPUG1MlQzOjNizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CAKI-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmDJTWM2OD1zNT61N\|Q3KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MKN28	NX;pVHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1fFS2lEPTB;MUWuOVQ4QSEQvF2=	NFr2OFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW13	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1TWNmlEPTB;MUWuOlE5KM7:TR?=	MlOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
A3-KAW	MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVzJR\|UxRTF3Lkm2PVch\|ryP	MkLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LU-65	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkLoTWM2OD1zNT65O\|Y5KM7:TR?=	NYr4RnFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
Calu-1	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWjJR\|UxRTF4LkCzOlgh\|ryP	Mm\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ST486	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY[0bFNQUUN3ME2xOk4xPDNzIN88US=>	NETnZ5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BB30-HNC	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlfXTWM2OD1zNj6xNlQ3KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EGI-1	M1\Hemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXTJR\|UxRTF4LkS0OkDPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SH-4	NVLueGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLMUm1yUUN3ME2xOk41PzNzIN88US=>	M4PoOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MN-60	M4nPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGLrSmtKSzVyPUG3MlIzQTdizszN	M1zXVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MPP-89	NF3OemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV72bZZXUUN3ME2xO{4zPDV7IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
A2780	NFnVeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWjJR\|UxRTF5LkSxN\|kh\|ryP	NGfQdYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Daoy	NUHBfYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV3JR\|UxRTF5LkS2PVUh\|ryP	M{TiflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2126	NYi3dpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF\B[JBKSzVyPUG3MlQ4PzFizszN	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1563	NX36dpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnfmTWM2OD1zNz60PVE4KM7:TR?=	M3WzO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
8-MG-BA	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\VO2lEPTB;MUeuOlY1QCEQvF2=	NETFeWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
786-0	NFjyVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLYflRtUUN3ME2xO{45OzV\|IN88US=>	NH\3O2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
AM-38	M1Lt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX7JR\|UxRTF5LkmzNFYh\|ryP	M{nvb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-824	NWTxcFFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2nX[GlEPTB;MUiuOFQ{PiEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MEL-30	NVThWlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1n3NmlEPTB;MUiuOVA5OiEQvF2=	NVeyT21QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CESS	NY\Oeo9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTF6Lke2NFkh\|ryP	M2XEbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BL-70	NUTUTlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4TrdGlEPTB;MUiuPFE2PiEQvF2=	NIDMTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2170	NVvwdmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV3EPJJDUUN3ME2xPE46OTd7IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HT-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzOTWM2OD1zOD65PFMh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BOKU	NX:2dW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn33TWM2OD1zOT6wN\|gyKM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HPAF-II	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MW\JR\|UxRTF7LkOwNVUh\|ryP	NHX0OFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KGN	NYLWcIZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIXGUWlKSzVyPUG5MlQ4PjVizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MC-CAR	NV3GOVBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYjJR\|UxRTF7Lk[zNVMh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BHT-101	NVyyPFRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXrJR\|UxRTF7Lke3O{DPxE1?	NHz4cok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1783	NVH4OVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXTJR\|UxRTF7Lke4NFYh\|ryP	NFP5N5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KP-N-YN	NFvj[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWPJR\|UxRTJyLkCyOlIh\|ryP	M4X5blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LU-165	NVXYTlR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkH2TWM2OD1{MD61OVcyKM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GOTO	M3e5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVfzWmNpUUN3ME2yNE43PDVzIN88US=>	NX\oN4tSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EFM-19	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoD1TWM2OD1{MT6wO\|E3KM7:TR?=	Ml7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CTV-1	M{\zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX65d2F2UUN3ME2yNU4yODV2IN88US=>	M3XHNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HEL	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2PJZmlEPTB;MkGuOFIyPiEQvF2=	M{W5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SNU-C2B	NUPVSWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4naeWlEPTB;MkGuOFI3KM7:TR?=	M3HqcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ECC4	NITsT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M160bWlEPTB;MkGuO\|A4KM7:TR?=	MlXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NEC8	M2L4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEniZYlKSzVyPUKxMlg{PjhizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KMOE-2	M4r1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;DdWhKSzVyPUKxMlg6OjFizszN	M2ezblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H524	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUHDS4dGUUN3ME2yNk4xQDB6IN88US=>	NXn2b3JzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
WSU-NHL	M1[ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV\JR\|UxRTJ{LkG1O\|ch\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SF126	NYfubIo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;MXGlEPTB;MkKuNlQ3QSEQvF2=	MoPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HOP-92	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUTJcmNpUUN3ME2yNk4{OTZ5IN88US=>	NYLaSWFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CTB-1	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{DaTmlEPTB;MkKuOFY4PyEQvF2=	NF\hUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-270	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{e0XGlEPTB;MkKuPVM2PyEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	NXLSfnViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHvQb3ZKSzVyPUKzMlE5PyEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Calu-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2\1UGlEPTB;MkOuNlEzQCEQvF2=	M1;yXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GAMG	NV\vVZV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rZUmlEPTB;MkOuNlM3PyEQvF2=	NGj5TWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1573	M4rnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3rvXWlEPTB;MkOuO\|QyPSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWTZSmtHUUN3ME2yOE4xOTl2IN88US=>	NHSxOIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TK10	NF;heVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlvtTWM2OD1{ND61NFE{KM7:TR?=	Ml7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB373-MEL-D	NH;yPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHe2PYpKSzVyPUK0MlYxPjRizszN	MmDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KALS-1	M1PuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYC5UnM2UUN3ME2yOE44OzJ5IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HUTU-80	NHTu[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYPJR\|UxRTJ3LkiwN\|Ih\|ryP	M1nNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HuP-T3	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXvJR\|UxRTJ4LkG2O\|Qh\|ryP	NHexXmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OE19	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIXzc2VKSzVyPUK2MlIyPTNizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
J82	NXvSZmpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3PpemlEPTB;Mk[uNlQ4OSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DU-4475	NWLZOGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVrJR\|UxRTJ4LkO4NVkh\|ryP	NEDXdlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DMS-53	NXvOdWRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV;JR\|UxRTJ4LkWxN\|gh\|ryP	MkPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-741	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MknNTWM2OD1{Nj64N\|Q1KM7:TR?=	MnTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW48	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUTiPZlyUUN3ME2yOk45QDJizszN	NIHkWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
IGR-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NITZcHZKSzVyPUK2Mlk{OzRizszN	MnTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
639-V	NFX6TplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYLoSZdmUUN3ME2yO{4xOjR3IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LK-2	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVjqdJY5UUN3ME2yO{41OTRzIN88US=>	Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2347	NGPPfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXXJR\|UxRTJ5Lkm2PVkh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2228	M3nqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3PSXWlEPTB;MkiuNFkxPSEQvF2=	NU\seVlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LS-123	NILoWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NET5OndKSzVyPUK4MlEzPjJizszN	Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
U031	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWjJR\|UxRTJ6LkK1NkDPxE1?	M3THSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1792	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XXSmlEPTB;MkiuOFczOSEQvF2=	M4S4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2087	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnLwTWM2OD1{OD63OVUzKM7:TR?=	M3;McVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2342	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\hR2lEPTB;MkmuOVIxQCEQvF2=	MmXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW626	NX3S[HBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnH5TWM2OD1{OT63OVYh\|ryP	NWnad3VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB2518-MEL	NXL6fYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NILlVZdKSzVyPUK5MlgyPSEQvF2=	NFH2N5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
RXF393	NULWcJptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1TLdWlEPTB;M{CuNFk2OiEQvF2=	NHXQW5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LC4-1	MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmW5TWM2OD1\|MD6zNFkzKM7:TR?=	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1694	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX;JR\|UxRTNyLk[2NlQh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
K5	NGX2UIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmX6TWM2OD1\|MD65O\|AzKM7:TR?=	NXrGd4tsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HDLM-2	NUWwS3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MojBTWM2OD1\|MD65O\|I2KM7:TR?=	M{HGRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BCPAP	M3L6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXvLWHdvUUN3ME2zNU45Ozd7IN88US=>	M4DLSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BC-3	NYDSXHEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVXp[nFlUUN3ME2zNk4yPDB\|IN88US=>	NVvJdlRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LB996-RCC	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPlcIpJUUN3ME2zNk4zOzV6IN88US=>	NV\jVotPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2009	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWLJR\|UxRTN{LkS5PFEh\|ryP	NHP3TmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HTC-C3	M1HJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFfwbFdKSzVyPUOzMlc2OTlizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LAMA-84	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\abWNKSzVyPUO0MlQ1ODdizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	NE\DOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEnvR5RKSzVyPUO0MlU4OTVizszN	M3ezVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
AN3-CA	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mor2TWM2OD1\|NT6wOVY5KM7:TR?=	MlXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1734	NFvS[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoD5TWM2OD1\|NT6yOVYyKM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Ca-Ski	M32zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYLSNoF1UUN3ME2zOU41OTBzIN88US=>	NU[0Nm9LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
U-266	NUXqXIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYHJR\|UxRTN3Lk[xNVQh\|ryP	NVn5dGR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SBC-5	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\KcWlEPTB;M{WuO\|c5OSEQvF2=	NXH5WWZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GT3TKB	NFjB[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3LaTmlEPTB;M{euNVE2KM7:TR?=	NI[wN4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MDA-MB-175-VII	NX7iNVdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX3JR\|UxRTN5LkKyOFgh\|ryP	NUnnN3dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PFSK-1	NYH4Ong3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NI\zc4lKSzVyPUO3MlI1OzVizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
IMR-5	NH;4V\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWjJR\|UxRTN5LkK0PFch\|ryP	NF7TRnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Daudi	M3ziTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWHJR\|UxRTN5LkO1PVch\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
A498	NHvpOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M161TmlEPTB;M{euO\|IyQCEQvF2=	M1nRcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SCC-4	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MY\JR\|UxRTN5Lke4OFMh\|ryP	M1LF[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-680N	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml;4TWM2OD1\|OD6yPFg2KM7:TR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MES-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWK5Z3ZTUUN3ME2zPE4{OjF3IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3;BWWlEPTB;M{iuOVQ6PSEQvF2=	M130W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LNCaP-Clone-FGC	M2ToOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1q1RWlEPTB;M{iuOVY{PyEQvF2=	NVzqb45XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-HEP-1	NUPFSo5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX;JR\|UxRTN6Lke4NlIh\|ryP	MnixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BPH-1	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MorkTWM2OD1\|OD64N\|I6KM7:TR?=	MmjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1755	M1Tiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1LUVWlEPTB;M{muOVgyPyEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LXF-289	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mlr0TWM2OD1\|OT64NFg1KM7:TR?=	NYTJc\|lVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW1088	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HwOmlEPTB;NECuNlExPyEQvF2=	MkPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MOLT-4	NFzmb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV7JR\|UxRTRyLkK5NFEh\|ryP	Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
AsPC-1	NH\ZRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFvKZmlKSzVyPUSwMlQ2QDNizszN	MnraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HOP-62	NHXsdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoLxTWM2OD12MD62OVY5KM7:TR?=	NInBd4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A172	MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYLUV\|ZCUUN3ME20NE45PTFzIN88US=>	M{n1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SN12C	NV3uVo5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH;nUoNKSzVyPUSwMlk{QDVizszN	NGXjbXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MDA-MB-231	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml7yTWM2OD12MD65PFk5KM7:TR?=	NYS4bGY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RPMI-2650	NEfiZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlixTWM2OD12MT6xOVk{KM7:TR?=	MnTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KYSE-140	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYTJR\|UxRTRzLkixNlMh\|ryP	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KINGS-1	NUXqTZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV;JR\|UxRTR{LkS2PVch\|ryP	NIixXok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HSC-3	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV;JR\|UxRTR{Lk[2OlEh\|ryP	NELadHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
PC-14	NWKzZlNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGT6Z4tKSzVyPUSzMlE5QDJizszN	Mlv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COR-L105	M13xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\tN2lEPTB;NEOuOlUxOiEQvF2=	NH\tUW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BE-13	NX;3WGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX3yXW9tUUN3ME20OE4zOzdzIN88US=>	MnfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H661	M2P4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fseGlEPTB;NESuNlk2QCEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
IST-MEL1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4C0ZmlEPTB;NESuN\|U6QSEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HCC1806	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfEOVg5UUN3ME20OE42QDd\|IN88US=>	MnjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-800	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MljETWM2OD12ND64OFU{KM7:TR?=	NULXV3dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
IST-SL2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH\aZYpKSzVyPUS1MlEzPDdizszN	NFPnfWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
8305C	M3nlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUfJR\|UxRTR3LkOwPUDPxE1?	M2TGUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
UACC-62	NFfZbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF\PVFFKSzVyPUS2MlI5PzVizszN	NULHPJd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
COR-L23	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWXJR\|UxRTR5LkG5PUDPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EFE-184	M{XpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnfkTWM2OD12Nz6zPFgh\|ryP	NEe4dlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DMS-114	NUG2ZndrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVvXUWU1UUN3ME20O{41OTR7IN88US=>	NXPMRpZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KYSE-520	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIfkbFdKSzVyPUS4MlU{OTVizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SNG-M	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWLJR\|UxRTR7LkSzOEDPxE1?	M1WzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A2058	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1nrS2lEPTB;NEmuOFg5PSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HEK293	M3z0PGZ2dmO2aX;uJIF{e2G7	M17DWlYxKG2rboO=	NFHw[HVKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGlITi1zIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdiliYYX0c5Bpd3OyaH;yfYxifGmxbjD0doFve2[nY4Tl[EBqdiCKRVuyPVMh[2WubIOgdJJmfHKnYYTl[EBnd3JiNkCgcYlveyCob3zsc5dm\CCkeTDJS2YuOSC\|dHnteYxifGmxbjDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IIH1ZY51cXSjdHn2[UBY\XO2ZYLuJIJtd3RiYX7hcJl{cXNuIFnDOVAhRSByLkCwNlgh\|ryPLh?=	Ml3UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUG3OVMoRjJ4OUWxO\|U{RC:jPh?=
Ba/F3	MWrGeY5kfGmxbjDhd5NigQ>?		NFr2NlFKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGlITi1zIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyIE2gNE4xODd4IN88UU4>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl3MUe1N{c,OjZ7NUG3OVM9N2F-
HEK293	NVzyW\|BITnWwY4Tpc44h[XO\|YYm=	NF\qWnk3OCCvaX7z	NYnWNYFsUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBqdnO3bHnuJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDmc4xtd3enZDDifUBKT0ZvMTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjCxNEBucW6\|IHL5JJF2[W62aYTheIl3\SCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTCwMlAyPiEQvF2u	NFLlbVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm1NVc2Oyd-Mk[5OVE4PTN:L3G+
A431	M2TqN2Z2dmO2aX;uJIF{e2G7		MVfJcohq[mm2aX;uJI9nKEmJRkHSJIlvfHKjY3XscJVt[XJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEF2M{GgZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSByLkCxPEDPxE1w	NVLx[HJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFY3PTVpPkKwN\|Q3PjV3PD;hQi=>
3T3	M3fk[mZ2dmO2aX;uJIF{e2G7		MYrJcohq[mm2aX;uJI9nKGi3bXHuJGlITjGUIHX4dJJme3OnZDDpckBud3W\|ZTCzWFMh[2WubIOgZpkhTUyLU1GgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{NDFOwG0v	Mn\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{NUG4NlQoRjJzMkWxPFI1RC:jPh?=
NIH 3T3	MoHvSpVv[3Srb36gZZN{[Xl?	NH6xWVkzKGi{cx?=	NXu5dlc5UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDJS2YuOVJib4\ldoV5eHKnc4Pl[EBqdiCvb4Xz[UBPUUhiM2SzJINmdGy\|IHHzd4V{e2WmIHHzJGlITjFvaX7keYNm\CCycn;0[YlvKHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKgbJJ{KHC{aX;yJJRwKEmJRkGgbY5lfWO2aX;uJI1m[XO3cnXkJIFnfGW{IEG1JI1qdnNiYomgSWxKW0FuIFnDOVAhRSByLkCyOEDPxE1w	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEeyNUc,OjR7MEC3NlE9N2F-
Ba/F3	M3;ybmZ2dmO2aX;uJIF{e2G7		MWHJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHnud5VtcW5icnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTBiPTCwMlEzPiEQvF2u	MoXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUG3OVMoRjJ4OUWxO\|U{RC:jPh?=
A673	MXfxTHRUKGG\|c3H5		MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NEfzU2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	M1HxbpFJXFNiYYPzZZk>		NVLFTlk6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	NWjqfY5weUiWUzDhd5NigQ>?		M2fPSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	Mn\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M2rIfpFJXFNiYYPzZZk>		MmjwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	MYnxTHRUKGG\|c3H5		NVjtNphjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	MoXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NFT3UolyUFSVIHHzd4F6		NXzsPJZXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MXrxTHRUKGG\|c3H5		NHTtR\|NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	M3;SdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NIj2bGZyUFSVIHHzd4F6		M2KzfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MoTMdWhVWyCjc4PhfS=>		M17pV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NEfqO5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NUfBOJh6eUiWUzDhd5NigQ>?		NVLrXnQ4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	M2exdpFJXFNiYYPzZZk>		NEfqZVdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	Mmm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M4O5c5FJXFNiYYPzZZk>		NYrqW2N3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MlLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP, AXL1717) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)